Deep venous thrombosis thrombolytics

Ouriel K, Kaul AF, Leonard MC. Clinical and economic outcomes in thrombolytic treatment of peripheral arterial occlusive disease and deep venous thrombosis. J Vase Surg. 2004 40 971-977. 

Home MK 3d, Chang R. Thrombolytic therapy for deep venous thrombosis JAMA 1999 282 2164-2166. 

Thrombolytics include tissue plasminogen activator (tPA, recombinant) and streptokinase (bacterial). They are used intravenously for short-term emergency management of coronary thromboses in myocardial infarction (MI), deep venous thrombosis, pulmonary embolism, and ischemic stroke (tPA). 

Immobilization of the enzyme urokinase has also been utilized [35-37], Urokinase is used chnically as a thrombolytic agent in the treatment of severe or deep venous thrombosis and occluded intravenous cannulas made with SPUs. 

Smith AG, Cornblath WT, Deveikis JP. Local thrombolytic therapy in deep cerebral venous thrombosis. Neurology 1997 48 1613-1619. 

The anticlotting drugs are used in the treatment of myocardial infarction and other acute coronary syndromes, atrial fibrillation, ischemic stroke, and deep vein thrombosis (DVT). The anticoagulant and thrombolytic drugs ate effective in treatment of both venous and arterial thrombosis. Antiplatelet dmgs are used primarily for treatment of arterial disease. 

---